TABLE 4.

Prediction of decline from NL with CSF biomarkers, a summary of findings.

First author, year	decliners (n)	non decliners (n)	Outcome measure	Predictor
Craig-Schapiro 2010 [138]	26	148	conversion from CDR=0 to CDR<0.	CSF YKL*-40/ Aß42 ratio predicted conversion
Desikan 2012 [140]	107 NL, n in groups not given		change in CDR or ADAS-Cog	low Aß42 predicted decline only in subjects who also had high p-tau
Fagan 2007 [22]	13	48	conversion from CDR=0 to CDR<0.	t-tau/ Aß42 and p-tau181/Aß42 predicted decline
Glodzik 2011 [138]	20	37	reduced memory performance	p-tau231 predicted decline in delayed recall performance.
Gustafson 2006 [135]	6	45	conversion to dementia or decline in MMSE	lower Aß42 levels associated with greater decline
Li 2007 [56]	4	43	conversion to MCI.	t-tau/Aß42 predicted conversion
Skoog 2003 [137]	7	35	conversion to dementia.	low Aß42 predicted conversion to dementia; Aß40 did not
Stomrud 2007 [138]	15	42	decline in MMSE, development of subjective memory impairment affecting quality of life.	low baseline Aß42 predicted decline at 3-year follow-up.
Visser 2009 [131]	149 NL, n in groups not given		change in memory or cognition composite score, MMSE, or conversion to AD	low Aß42 was best predictor of decline

^*YKL-40: human cartilage glycoprotein-39